India AMR Co-Development Programme: antibacterial innovations from lab to patient

The India AMR Co-Development Programme accepts Indian antibacterial innovations at proof-of-concept stage or later through December 31, 2026. It offers ₹10 lakh upon a co-development agreement plus translational development support for academic teams, researchers and startups. Early exploratory discovery, diagnostics, disinfectants, vaccines, antifungals and antivirals are excluded. Phage eligibility is not explicitly stated; applicants should confirm fit with the programme.